de Lima, M <br/><br/>
Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.  [electronic resource] 

 -  Leukemia  Feb 2008 
 - 258-64 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article 
<br/><br/><label>ISSN: </label>1476-5551 
<br/><br/><label>Standard No.: </label>10.1038/sj.leu.2405014  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Aminoglycosides--administration & dosage<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Antigens, CD<br/>Antigens, Differentiation, Myelomonocytic<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Disease-Free Survival<br/>Female<br/>Gemtuzumab<br/>Graft Survival<br/>Hematopoietic Stem Cell Transplantation--methods<br/>Humans<br/>Leukemia, Myeloid--mortality<br/>Male<br/>Melphalan--administration & dosage<br/>Middle Aged<br/>Myelodysplastic Syndromes--mortality<br/>Remission Induction<br/>Sialic Acid Binding Ig-like Lectin 3<br/>Survival Rate<br/>Transplantation, Homologous<br/>Vidarabine--administration & dosage